Security key
62818Q302
MUSTANG BIO, INC. - Common Stock, $0.0001 Par Value (MBIO)
CUSIP: 62818Q302
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, $0.0001 Par Value
- Total 13F shares
- 74,262
- Total 13F value
- $70,926
- Share change
- -39,597
- SEC-reported price per share
- $0.96
- Number of holders
- 16
- Value change
- -$51,419
- Number of buys
- 7
- Number of sells
- 5
- Shares outstanding
- 6,715,538
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
16
Top holders
10
MBIO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
MUSTANG BIO, INC. SEC filings
MUSTANG BIO, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 62818Q302
Recent filing periods:
Ownership snapshot
Top reported holders of MBIO - MUSTANG BIO, INC. - Common Stock, $0.0001 Par Value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fortress Biotech, Inc.
Disclosed value leader
Fortress Biotech, Inc.
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
Lead comparable stake: 12%
13D/G row: Fortress Biotech, Inc.
Showing 1-6 of 15 holder rows.
Quick read
Fortress Biotech, Inc. leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fortress Biotech, Inc.'s linked filing trail.
Comparable ownership
Top 5
Fortress Biotech, Inc.
12%
INTRACOASTAL CAPITAL, LLC
5%
ARMISTICE CAPITAL, LLC
5%
UBS Group AG
0.71%
Anson Funds Management LP
0.68%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. |
13D/G
|
12%
|
$1,708,057
6,569,450 shares
|
$0 | 31 Dec 2024 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
$491,647
185,527 shares
|
-$134,951 | 30 Jun 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$149,887
129,213 shares
|
-$5,773,406 | 31 Mar 2025 |
| UBS Group AG |
13F
Company
|
0.71%
|
$59,426
47,540 shares
|
— | 31 Mar 2025 |
| Anson Funds Management LP |
13F
Company
|
0.68%
|
$57,145
45,716 shares
|
— | 31 Mar 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.23%
|
$19,708
15,767 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
16
Shares
74,262
Rows available
16
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
15
Q2 2025 holders
16
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend